Basal cell carcinoma screening: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Basal cell carcinoma}} | |||
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D. | |||
{{ | ==Overview== | ||
The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening. | |||
==Basal Carcinoma Screening== | |||
The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening<ref>{{cite journal|title=Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=150|issue=3|year=2009|pages=188|issn=0003-4819|doi=10.7326/0003-4819-150-3-200902030-00008}}</ref>. | |||
Nevertheless, the Task Force members state that “clinicians should remain alert for skin lesions with malignant features noted in the context of physical examinations performed for other purposes,” and recognize that “even without formal screening programs, mortality from basal cell and squamous cell carcinoma is low compared with mortality from melanoma, but early detection and treatment may reduce morbidity and disfigurement from these cancers”<ref>http://www.aafp.org/afp/2004/1015/p1481.html#afp20041015p1481-b22</ref>. | |||
==References== | ==References== | ||
| Line 9: | Line 17: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Revision as of 15:08, 27 July 2015
|
Basal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Basal cell carcinoma screening On the Web |
|
American Roentgen Ray Society Images of Basal cell carcinoma screening |
|
Risk calculators and risk factors for Basal cell carcinoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.
Overview
The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening.
Basal Carcinoma Screening
The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening[1].
Nevertheless, the Task Force members state that “clinicians should remain alert for skin lesions with malignant features noted in the context of physical examinations performed for other purposes,” and recognize that “even without formal screening programs, mortality from basal cell and squamous cell carcinoma is low compared with mortality from melanoma, but early detection and treatment may reduce morbidity and disfigurement from these cancers”[2].
References
- ↑ "Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 150 (3): 188. 2009. doi:10.7326/0003-4819-150-3-200902030-00008. ISSN 0003-4819.
- ↑ http://www.aafp.org/afp/2004/1015/p1481.html#afp20041015p1481-b22